Ambrisentan, sold under the brand name Letairis, is an oral medication used to treat pulmonary arterial hypertension (PAH), a rare and serious condition that affects the arteries in the lungs and the right side of the heart. As an endothelin receptor antagonist (ERA), ambrisentan helps lower blood pressure in the lungs and improves patients’ ability to exercise and perform daily activities.
This article will explain what ambrisentan is, how it works, its FDA-approved uses, proper dosage guidelines, common side effects, and how patients can access this treatment through a specialty pharmacy.
What Is Ambrisentan?
Ambrisentan is a prescription medication that targets type A endothelin receptors, which play a key role in narrowing blood vessels and raising blood pressure in the lungs. By blocking these receptors, ambrisentan helps dilate pulmonary arteries, improving blood flow and reducing the strain on the heart.
Ambrisentan is typically prescribed for WHO Group 1 pulmonary arterial hypertension (PAH) and is often used as part of a combination therapy plan. It is only available through a restricted distribution program and dispensed by specialty pharmacies.
FDA-Approved Use of Ambrisentan
Ambrisentan was approved by the U.S. Food and Drug Administration (FDA) for the treatment of:
- Pulmonary Arterial Hypertension (PAH)
(World Health Organization Group 1) to:- Improve exercise capacity
- Delay clinical worsening
It is indicated for both adult patients and may be used alone or with other PAH medications, such as phosphodiesterase-5 inhibitors (e.g., tadalafil).
How Ambrisentan Works
Ambrisentan works by blocking the effects of endothelin-1, a naturally occurring substance that causes blood vessels in the lungs to constrict. Overactivity of endothelin-1 is a key factor in PAH.
By blocking endothelin type A receptors, ambrisentan:
- Relaxes and widens blood vessels in the lungs
- Reduces pulmonary vascular resistance (PVR)
- Lowers mean pulmonary artery pressure
- Improves cardiac output and oxygen delivery
These effects help PAH patients breathe more easily, tolerate more physical activity, and slow the progression of the disease.
Ambrisentan Dosage and Administration
Ambrisentan is taken once daily, with or without food.
Recommended Dosage:
- Initial and maintenance dose: 5 mg once daily
- If tolerated: May be increased to 10 mg once daily
It is important to take ambrisentan at the same time every day, and it should be swallowed whole with water. Dose adjustments may be necessary in patients with liver impairment.
Common Side Effects of Ambrisentan
Most Common Side Effects:
- Swelling of the hands, feet, or ankles (peripheral edema)
- Nasal congestion
- Headache
- Flushing
- Sinusitis
Serious Risks:
- Liver function abnormalities (monitoring required)
- Anemia (low red blood cell count)
- Decreased sperm count in men
- Teratogenicity (can cause serious birth defects)
Pregnancy Warning:
Ambrisentan is contraindicated in pregnancy. Women of childbearing potential must use effective contraception and undergo monthly pregnancy tests as part of the REMS (Risk Evaluation and Mitigation Strategy) program.
Monitoring and Safety Requirements
Patients taking ambrisentan must be enrolled in the Letairis REMS Program, which includes:
- Monthly pregnancy testing (for women)
- Regular liver function monitoring
- Routine blood tests to check hemoglobin levels
These safety protocols are managed through a certified specialty pharmacy, which also provides education, delivery, and insurance support.
Access Through Specialty Pharmacy
Ambrisentan is not available at regular retail pharmacies. It must be dispensed by a specialty pharmacy that participates in the Letairis REMS program.
Benefits of specialty pharmacy services include:
- Home delivery and automatic refills
- Assistance with prior authorization
- Help enrolling in manufacturer copay assistance or financial support programs
- Direct access to pharmacists trained in PAH treatment
Ask your healthcare provider to refer you to a specialty pharmacy if you are prescribed ambrisentan.
Conclusion
Ambrisentan (Letairis) is a proven treatment option for pulmonary arterial hypertension that helps improve exercise ability, delay disease progression, and support better quality of life. By targeting the endothelin pathway, it reduces the stress on the heart and lungs caused by high pulmonary blood pressure.
However, due to serious safety concerns particularly during pregnancy, ambrisentan is only available through a REMS program and requires close medical supervision. If you or someone you care for is living with PAH, speak to a pulmonologist or cardiologist about whether ambrisentan is a suitable part of your treatment plan.
